CurrentKaiser PermanentePolicy N/A

Clinical Review Criteria — Vectra DA (Multiple Biomarker Disease Activity [MBDA])

Clinical review criteria governing medical necessity and coverage determinations for the Vectra DA multibiomarker disease activity (MBDA) blood test for rheumatoid arthritis for Kaiser Foundation Health Plan of Washington members and providers.

Policy Summary

PayerKaiser Permanente

PolicyVectra DA (MBDA) clinical review criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateOct 7, 2025

Key ActionIf requesting this service, provide the last 6 months of clinical notes from the requesting provider and/or consulting specialist to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12analytes measured

1-100MBDA score range

81490CPT code

12/21/2015MTAC review

InsufficientMTAC conclusion

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage by member type

Coverage determinations are as follows:

Medicare coverage: Medicare members: Vectra DA (CPT 81490) is considered medically necessary when criteria in the applicable policy statements are met (refer to LCD A54505 and applicable CMS guidance).

See chunks 1 and 9 for Medicare stance and reference to LCD A54505.

Non-Medicare coverage: Non-Medicare members: Vectra DA (CPT 81490) is considered not medically necessary due to insufficient evidence of clinical validity, clinical utility, and impact on patient management or outcomes.

See chunks 2 and 8 for evidence conclusion and non‑Medicare coverage stance.

The Vectra DA (MBDA) test is not intended or validated to diagnose rheumatoid arthritis. It was developed to provide a multibiomarker assessment of disease activity and is intended to be used only as an adjunct to standard clinical assessment, not as a standalone diagnostic tool. Additionally, the test is not supported for routine monitoring in place of established clinical indices unless there is clear evidence that its results change management or improve outcomes.

For non‑Medicare members, the Vectra DA test is considered not medically necessary because the published evidence is insufficient to demonstrate that the test improves patient management or long‑term outcomes compared with standard care. Technology assessment concluded there is insufficient evidence of clinical validity and utility, and therefore routine coverage for non‑Medicare members is not supported.

As a result, claims for Vectra DA (CPT 81490) for non‑Medicare members may be denied when submitted for the purpose of guiding treatment decisions or routine monitoring, absent documentation demonstrating impact on clinical management beyond standard assessment.

Provider Actions and Billing Guidance

Note

Coverage stance — Medicare members

For Medicare members: follow applicable CMS guidance and LCD A54505 (Noridian) for medical necessity review; these services require review and are considered medically necessary only when the LCD/coverage article criteria are met.

Applicable codes: CPT 81490

Denial Risk

Coverage stance — Non‑Medicare members

For Non‑Medicare members: the Vectra DA (MBDA) test is considered Not Medically Necessary due to insufficient evidence of clinical validity and impact on patient management; submit a medical necessity justification if requesting review.

Non‑Medicare coverage status: Not Medically Necessary
Affected code: CPT 81490

Documentation Required

Required clinical documentation

If requesting this service, include the last 6 months of clinical notes from the requesting provider and/or consulting specialist to support medical necessity.

Attach clinical notes (last 6 months) from requesting provider and/or consulting specialist

Denial Risk

Denial risk and operational note

Denial risk: Non‑Medicare requests are likely to be denied when evidence of clinical utility or impact on management is not provided. Kaiser Technology Assessment concluded insufficient evidence to support use; provide strong, case‑specific rationale and documentation if requesting an exception.

Denial condition: insufficient evidence of safety, validity, or improved outcomes for Non‑Medicare members
Operational note: Medicare reviews rely on LCD A54505 — follow LCD criteria for medical necessity determinations

Background

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which tight control of disease activity is important to prevent joint damage and disability. Standard practice uses composite clinical indices (for example, DAS28, CDAI, SDAI) that combine clinical findings, laboratory measures, and patient‑reported outcomes to assess activity and guide treatment.

Vectra DA is a commercially available blood test that measures the serum concentration of 12 biomarkers and combines them via an algorithm to produce an MBDA score on a scale of 1–100 intended to reflect RA disease activity. Although studies report a moderate correlation with DAS28‑CRP, technology assessment found insufficient evidence that Vectra DA provides equivalent or superior clinical validity or that its use leads to improved management or patient outcomes.

Definitions

inv-10: Vectra DA (MBDA) — test components and score interpretation

Analytes measured12 serum biomarkers: VCAM-1, EGF, VEGF-A, IL-6, TNF‑RI, MMP‑1, MMP‑3, YKL‑40, SAA, CRP, leptin, resistin

Algorithm outputMultibiomarker disease activity (MBDA) score generated by an algorithm combining the 12 biomarkers

Score range1–100 reported MBDA score range

Score interpretation1–29 = low disease activity; 30–44 = moderate disease activity; 45–100 = high disease activity

Intended useAid in assessment of RA disease activity in adults when used with standard clinical assessment; not intended or validated to diagnose RA

inv-11: Composite RA disease activity indices (CDAI, DAS28, SDAI, RAPID-3) definition

DefinitionComposite RA disease activity indices are clinical tools that combine clinical, laboratory, and patient-reported measures to assess rheumatoid arthritis disease activity

Examples (recommended by ACR)CDAI, DAS28, PAS, PAS-II, RAPID-3, SDAI

Components includedQuantitative joint counts, patient-reported outcomes, physician examination, and laboratory tests such as ESR and CRP

LimitationsCan be complex, subject to intra-/inter-observer variability, may miss subclinical synovial damage, and can be influenced by cumulative damage or non‑RA conditions